Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, Proteome Software, Pressure Biosciences, AnaSpec

Agilent Technologies and Proteome Software said this week that Proteome’s Scaffold 2.1 software now supports the processing of search results from Agilent’s Spectrum Mill protein database search engine.
As a result, researchers who load Spectrum Mill data files into Scaffold will be able to compare Spectrum Mill results with those of Mascot, Sequest, Phenyx, OMSSA and X! Tandem search engines.
Spectrum Mill searches for MS and MS/MS data in protein databases in high-throughput fashion. Scaffold validates peptides and proteins from MS/MS data, combines results from multiple search engines and graphically displays identifications in biologically relevant formats.

Pressure Biosciences this week released Proteolysis (Trypsin) PrEP, an “enhanced trypsin digestion application.”
The application is part of the company’s products using pressure cycling technology which uses pressure for sample preparation.

AnaSpec introduced 234 new peptides this week. They include Caspase 10 (CT), ER-beta (IN), and p53 (pSer6) peptide, human.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.